Interactive Effects of HIV/AIDS, Body Mass, and Substance Abuse on the Frontal Brain: a P300 Study

Overview

Journal Psychiatry Res

Specialty Psychiatry

Date 2010 Jun 29

PMID 20580839

Citations 10

Authors

Lance O Bauer

Affiliations

Soon will be listed here.

Abstract

In view of the rising prevalence of an overweight body mass among patients living with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), clinicians must now be mindful of possible adverse outcomes resulting from the co-occurrence. The present study was designed to examine the additive and interactive effects of HIV/AIDS and an excess body mass, as well as the additional contributions of substance abuse or dependence. The dependent variable was brain function estimated by the measurement of P300 electroencephalographic potentials. P300 potentials were recorded during a task designed to elicit subcomponents with frontal (P300a) and both frontal and non-frontal (P300b) generators. Analyses revealed greater frontal P300a latencies among the 102 HIV-1 seropositive versus the 68 seronegative participants. In addition, frontal P300a latency was further increased by a synergistic interaction of HIV-1 serostatus with a body mass index (BMI)≥25 kg/m². A history of substance abuse/dependence did not alter these changes. However, it did combine with HIV/AIDS to produce a smaller P300a amplitude than was seen in participants with neither disorder. The findings suggest that white matter changes accompanying an excess BMI may exacerbate those that attend HIV/AIDS and thereby slow down frontal brain function. Substance abuse, likewise, interacts with HIV/AIDS but may impair frontal brain function via a different mechanism.

Citing Articles

Application status and prospects of multimodal EEG-fMRI in HIV-associated neurocognitive disorders.

Chen J, Luo H, Liu J, Wang W, Ma J, Hou C Front Neurol. 2024; 15:1479197.

PMID: 39703361 PMC: 11655344. DOI: 10.3389/fneur.2024.1479197.

Effects of Human Immunodeficiency Virus Infection and Former Cocaine Dependence on Neuroanatomical Measures and Neurocognitive Performance.

Wakim K, Freedman E, Tivarus M, Christensen Z, Molholm S, Foxe J Neuroscience. 2022; 502:77-90.

PMID: 35963584 PMC: 9588737. DOI: 10.1016/j.neuroscience.2022.08.008.

Assessing combinatorial effects of HIV infection and former cocaine dependence on cognitive control processes: A high-density electrical mapping study of response inhibition.

Wakim K, Freedman E, Molloy C, Vieyto N, Cao Z, Foxe J Neuropharmacology. 2021; 195:108636.

PMID: 34090915 PMC: 8820017. DOI: 10.1016/j.neuropharm.2021.108636.

Meghdadi A, Berka C, Richard C, Rupp G, Smith S, Karic M Clin Neurophysiol. 2021; 132(2):598-611.

PMID: 33573761 PMC: 9045835. DOI: 10.1016/j.clinph.2020.11.026.

EEG-Based Neurocognitive Metrics May Predict Simulated and On-Road Driving Performance in Older Drivers.

Rupp G, Berka C, Meghdadi A, Karic M, Casillas M, Smith S Front Hum Neurosci. 2019; 12:532.

PMID: 30697156 PMC: 6341028. DOI: 10.3389/fnhum.2018.00532.

References

Cardenas V, Chao L, Blumenfeld R, Song E, Meyerhoff D, Weiner M . Using automated morphometry to detect associations between ERP latency and structural brain MRI in normal adults. Hum Brain Mapp. 2005; 25(3):317-27. PMC: 2443725. DOI: 10.1002/hbm.20103. View

McDermott A, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S . Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr. 2001; 74(5):679-86. DOI: 10.1093/ajcn/74.5.679. View

Tang A, Jacobson D, Spiegelman D, Knox T, Wanke C . Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr. 2005; 40(1):70-6. DOI: 10.1097/01.qai.0000159627.54149.2e. View

Pfefferbaum A, Rosenbloom M, Adalsteinsson E, Sullivan E . Diffusion tensor imaging with quantitative fibre tracking in HIV infection and alcoholism comorbidity: synergistic white matter damage. Brain. 2006; 130(Pt 1):48-64. DOI: 10.1093/brain/awl242. View

. State-specific prevalence of obesity among adults--United States, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57(28):765-8. View

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B . Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007; 45(1):111-9. DOI: 10.1086/518619. View

Tang A, Forrester J, Spiegelman D, Knox T, Tchetgen E, Gorbach S . Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31(2):230-6. DOI: 10.1097/00126334-200210010-00014. View

Chao L, Lindgren J, Flenniken D, Weiner M . ERP evidence of impaired central nervous system function in virally suppressed HIV patients on antiretroviral therapy. Clin Neurophysiol. 2004; 115(7):1583-91. PMC: 2367143. DOI: 10.1016/j.clinph.2004.02.015. View

Brooner R, Bigelow G, Greenfield L, Strain E, Schmidt C . Intravenous drug abusers with antisocial personality disorder: high rate of HIV-1 infection. NIDA Res Monogr. 1991; 105:488-9. View

10.

Larussa D, Lorenzini P, Cingolani A, Bossolasco S, Grisetti S, Bongiovanni M . Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. AIDS Res Hum Retroviruses. 2006; 22(5):386-92. DOI: 10.1089/aid.2006.22.386. View

11.

Thompson P, Dutton R, Hayashi K, Lu A, Lee S, Lee J . 3D mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. Neuroimage. 2006; 31(1):12-23. DOI: 10.1016/j.neuroimage.2005.11.043. View

12.

Justman J, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt R . Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003; 32(3):298-302. DOI: 10.1097/00126334-200303010-00009. View

13.

Jacobson D, Tang A, Spiegelman D, Thomas A, Skinner S, Gorbach S . Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006; 43(4):458-66. DOI: 10.1097/01.qai.0000243093.34652.41. View

14.

Bing E, Burnam M, Longshore D, Fleishman J, Sherbourne C, London A . Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001; 58(8):721-8. DOI: 10.1001/archpsyc.58.8.721. View

15.

McCarley R, Salisbury D, Hirayasu Y, Yurgelun-Todd D, Tohen M, Zarate C . Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry. 2002; 59(4):321-31. DOI: 10.1001/archpsyc.59.4.321. View

16.

Mulligan K, Anastos K, Justman J, Freeman R, Wichienkuer P, Robison E . Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2004; 38(1):18-22. DOI: 10.1097/00126334-200501010-00004. View

17.

Bauer L . A family history of psychopathology modifies the decrement in cognitive control among patients with HIV/AIDS. Brain Cogn. 2008; 67(1):103-14. PMC: 2442883. DOI: 10.1016/j.bandc.2007.12.004. View

18.

McLellan A, Luborsky L, Woody G, OBrien C . An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980; 168(1):26-33. DOI: 10.1097/00005053-198001000-00006. View

19.

Dworkin M, Williamson J . AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr. 2003; 33(2):267-73. DOI: 10.1097/00126334-200306010-00024. View

20.

Dever L, Oruwari P, Figueroa W, ODonovan C, Eng R . Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother. 2000; 34(5):580-4. DOI: 10.1345/aph.19231. View